Clinical Trial Update: PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma [Phase 1]

View source ↗

Summary

Phase 1 biomarker study evaluating nivolumab with ipilimumab, and nivolumab in combination with ipilimumab, in advanced/metastatic melanoma; study completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced Melanoma, Metastatic Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2019-12-03